May your titration stay gradual, your side effects stay mild, and your protocols stay evidence-based.
The review thoroughly examines both clinical and practical evidence regarding the use of c-MET inhibitors alongside PD-1/PD-L1 inhibitors, emphasizing that focusing on c-MET with immunotherapy enhances the effectiveness of treating MET tumors exhibiting elevated PD-L1 expression
The effects of this can be seen in several major organs (5)
Immunomodulation of tumor microenvironment by arginine-loaded iron oxide nanoparticles for gaseous immunotherapy
Dougnon G, Matsui H (2025) Lipofuscin accumulation in aging and neurodegeneration: a potential timebomb overlooked in Alzheimers disease
National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis